{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:15:56Z","timestamp":1795032956897,"version":"4.10.2"},"reference-count":14,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.3201\/eid2502.170745","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T12:05:06Z","timestamp":1546517106000},"page":"316-320","source":"Crossref","is-referenced-by-count":39,"title":["Clinical Manifestations, Antimicrobial Drug Susceptibility Patterns, and Outcomes in Melioidosis Cases, India"],"prefix":"10.3201","volume":"25","author":[{"given":"Maria","family":"Koshy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjeera","family":"Jagannati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravikar","family":"Ralph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punitha","family":"Victor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thambu","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"Sathyendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Veeraraghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2502.170745-201901160718-R1","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1056\/NEJMra1204699","article-title":"Melioidosis.","volume":"367","author":"Wiersinga","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2502.170745-201901160718-R2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00001432-200204000-00005","article-title":"Melioidosis.","volume":"15","author":"Dance","year":"2002","journal-title":"Curr Opin Infect Dis"},{"key":"key-10.3201\/eid2502.170745-201901160718-R3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1128\/CMR.18.2.383-416.2005","article-title":"Melioidosis: epidemiology, pathophysiology, and management.","volume":"18","author":"Cheng","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"key-10.3201\/eid2502.170745-201901160718-R4","doi-asserted-by":"publisher","first-page":"e900","DOI":"10.1371\/journal.pntd.0000900","article-title":"The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study.","volume":"4","author":"Currie","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"key-10.3201\/eid2502.170745-201901160718-R5","doi-asserted-by":"publisher","first-page":"15008","DOI":"10.1038\/nmicrobiol.2015.8","article-title":"Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis.","volume":"1","author":"Limmathurotsakul","year":"2016","journal-title":"Nat Microbiol"},{"key":"key-10.3201\/eid2502.170745-201901160718-R6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0035-9203(00)90333-X","article-title":"Melioidosis: acute and chronic disease, relapse and re-activation.","volume":"94","author":"Currie","year":"2000","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.3201\/eid2502.170745-201901160718-R7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1258\/td.2009.090093","article-title":"The clinical profile and predictors of mortality in patients with melioidosis in South India.","volume":"40","author":"Chrispal","year":"2010","journal-title":"Trop Doct"},{"key":"key-10.3201\/eid2502.170745-201901160718-R8","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1001\/jama.286.14.1754","article-title":"Serial evaluation of the SOFA score to predict outcome in critically ill patients.","volume":"286","author":"Ferreira","year":"2001","journal-title":"JAMA"},{"key":"key-10.3201\/eid2502.170745-201901160718-R9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1086\/318116","article-title":"Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature.","volume":"31","author":"Currie","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2502.170745-201901160718-R10","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1016\/j.ijid.2012.02.012","article-title":"Emerging clinico-epidemiological trends in melioidosis: analysis of 95 cases from western coastal India.","volume":"16","author":"Vidyalakshmi","year":"2012","journal-title":"Int J Infect Dis"},{"key":"key-10.3201\/eid2502.170745-201901160718-R11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1086\/520223","article-title":"Risk factors for melioidosis and bacteremic melioidosis.","volume":"29","author":"Suputtamongkol","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2502.170745-201901160718-R12","doi-asserted-by":"publisher","first-page":"e54961","DOI":"10.1371\/journal.pone.0054961","article-title":"Host responses to melioidosis and tuberculosis are both dominated by interferon-mediated signaling.","volume":"8","author":"Koh","year":"2013","journal-title":"PLoS One"},{"key":"key-10.3201\/eid2502.170745-201901160718-R13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/bmb\/ldr007","article-title":"Melioidosis: a clinical overview.","volume":"99","author":"Limmathurotsakul","year":"2011","journal-title":"Br Med Bull"},{"key":"key-10.3201\/eid2502.170745-201901160718-R14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(13)61951-0","article-title":"Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial.","volume":"383","author":"Chetchotisakd","year":"2014","journal-title":"Lancet"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/25\/2\/17-0745_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:15:57Z","timestamp":1795029357000},"score":1,"resource":{"primary":{"URL":"http:\/\/wwwnc.cdc.gov\/eid\/article\/25\/2\/17-0745_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2502.170745","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}